The FINANCIAL -- The Supervisory Board of Allianz Deutschland AG today named Dr. Klaus-Peter Röhler as Chairman of the Management Board (CEO) and successor to Dr. Manfred Knof, effective January 1, 2018.
It was mutually agreed to follow Manfred Knof’s request and to relieve him of his position as CEO of Allianz Deutschland effective December 31, 2017. Until then, Manfred will help to ensure a smooth leadership transition. After that, he will take some time off for health reasons, according to Allianz.
Klaus-Peter Röhler, 52, has been CEO of Allianz Italia SpA since 2014, a post he assumed after serving as CEO of Allianz Suisse for two years. Klaus-Peter Röhler started his career at Allianz in 1996. The Allianz Italia Board of Directors decided to appoint Giacomo Campora, 50, as CEO of Allianz Italia as of January 1, 2018. Currently, Giacomo Campora is General Manager in charge of Market and Distribution at Allianz Italia and CEO of Allianz Bank Financial Advisors.
Manfred Knof, 52, has been CEO of Allianz Deutschland AG since April, 2015. Prior to this, he served as regional CEO of Allianz in Central and Eastern Europe. Before that, in 2012, he was appointed to the Allianz Germany Management Board as a member responsible for operations and claims and later also became Chief Operating Officer. Manfred Knof, born in Cologne, was CEO of Allianz Suisse from 2006 to 2011. He started his career at Allianz in 1995.
Oliver Bäte, Chief Executive Officer of Allianz SE, said: “I would like to thank Manfred Knof for his successful leadership at Allianz Deutschland. The company played a leading role time and again in implementing the Renewal Agenda. I regret his decision but respect and support it and wish Manfred all the best for the future. I am convinced that we have found the right successor in Klaus-Peter Röhler. He has a wealth of experience in the Property & Casualty business as well as in Life insurance. Under his leadership, Allianz in Italy made great strides in the digitalization of our Italian business.”
The decisions await standard checks and approvals by the relevant regulatory authorities.